The identification of driver and resistance mutations located in the tyrosine kinase domain of EGFR in a subset of non-small cell lung cancer (NSCLC) is necessary to guide patient treatment options and to predict prognosis [1–3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.